MiNK Therapeutics (INKT) Competitors $26.01 -2.00 (-7.14%) As of 01:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. ELVN, GPCR, ARDX, PHVS, COLL, AKBA, PRAX, AMPH, LENZ, and CDTXShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), Ardelyx (ARDX), Pharvaris (PHVS), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Praxis Precision Medicines (PRAX), Amphastar Pharmaceuticals (AMPH), LENZ Therapeutics (LENZ), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Its Competitors Enliven Therapeutics Structure Therapeutics Ardelyx Pharvaris Collegium Pharmaceutical Akebia Therapeutics Praxis Precision Medicines Amphastar Pharmaceuticals LENZ Therapeutics Cidara Therapeutics Enliven Therapeutics (NASDAQ:ELVN) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Is ELVN or INKT more profitable? MiNK Therapeutics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -31.84% -30.09% MiNK Therapeutics N/A N/A -140.72% Do institutionals and insiders have more ownership in ELVN or INKT? 95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 22.5% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend ELVN or INKT? Enliven Therapeutics currently has a consensus price target of $41.20, suggesting a potential upside of 87.91%. MiNK Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 44.18%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enliven Therapeutics is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00MiNK Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media refer more to ELVN or INKT? In the previous week, MiNK Therapeutics had 19 more articles in the media than Enliven Therapeutics. MarketBeat recorded 30 mentions for MiNK Therapeutics and 11 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.57 beat MiNK Therapeutics' score of 0.10 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiNK Therapeutics 4 Very Positive mention(s) 6 Positive mention(s) 14 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Which has stronger earnings and valuation, ELVN or INKT? Enliven Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$89.02M-$1.92-11.42MiNK TherapeuticsN/AN/A-$9.51M-$2.52-10.32 Which has more volatility and risk, ELVN or INKT? Enliven Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. SummaryEnliven Therapeutics beats MiNK Therapeutics on 9 of the 13 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$103.86M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-10.3320.3528.6119.64Price / SalesN/A304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book-5.277.718.185.63Net Income-$9.51M-$55.11M$3.23B$257.73M7 Day Performance241.11%0.68%-0.25%0.07%1 Month Performance253.40%8.22%5.40%8.32%1 Year Performance147.71%-2.64%26.35%13.78% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.5026 of 5 stars$26.01-7.1%$37.50+44.2%+145.7%$103.86MN/A-10.3330News CoverageAnalyst DowngradeELVNEnliven Therapeutics2.7909 of 5 stars$22.81+0.1%$41.20+80.7%-13.7%$1.12BN/A-11.8850GPCRStructure Therapeutics2.8996 of 5 stars$19.32+2.2%$76.17+294.2%-56.8%$1.11BN/A-22.21136Positive NewsARDXArdelyx4.0638 of 5 stars$4.65-1.1%$10.89+134.4%-24.4%$1.11B$333.61M-21.0290Analyst RevisionPHVSPharvaris1.5293 of 5 stars$20.85+5.1%$36.20+73.6%+28.7%$1.09BN/A-6.9330COLLCollegium Pharmaceutical4.2854 of 5 stars$32.66-1.0%$43.75+34.0%+0.7%$1.05B$631.45M26.77210Buyback AnnouncementAKBAAkebia Therapeutics3.6543 of 5 stars$3.95-0.9%$6.75+71.1%+196.2%$1.04B$160.18M-18.78430PRAXPraxis Precision Medicines2.2462 of 5 stars$50.85+1.1%$94.11+85.1%+1.8%$1.03B$8.55M-4.70110News CoverageAnalyst RevisionAMPHAmphastar Pharmaceuticals4.292 of 5 stars$21.72-2.2%$32.33+48.9%-45.4%$1.02B$731.97M7.872,028LENZLENZ Therapeutics1.3099 of 5 stars$35.68+4.1%$46.60+30.6%+50.9%$1.00BN/A-20.16110Analyst RevisionCDTXCidara Therapeutics4.175 of 5 stars$49.38-2.9%$57.14+15.7%+311.9%$995.50M$1.27M-1.6890 Related Companies and Tools Related Companies Enliven Therapeutics Competitors Structure Therapeutics Competitors Ardelyx Competitors Pharvaris Competitors Collegium Pharmaceutical Competitors Akebia Therapeutics Competitors Praxis Precision Medicines Competitors Amphastar Pharmaceuticals Competitors LENZ Therapeutics Competitors Cidara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INKT Stock Alerts